A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Study identifier:D7420C00002

ClinicalTrials.gov identifier:NCT06160414

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Metformin, Rosuvastatin, ALXN2080

Sex

All

Actual Enrollment

20

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 07 Dec 2023
Primary Completion Date: 05 Feb 2024
Study Completion Date: 05 Feb 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria